Login to Your Account

Earnings Roundup

Thursday, April 26, 2012

• Dyax Corp., of Burlington, Mass., reported net sales of hereditary angioedema drug Kalbitor (ecallantide) totaling $8 million for the first three months of 2012, a 14 percent jump over the fourth quarter of 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription